Abstracts tagged "spondyloarthritis"

Abstract Number: 0407 • ACR Convergence 2022
Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Paras Karmacharya¹, Sonia Gupta², Ravi Shahukhal³, Raju Khanal⁴, Hassan Murad⁵ and Lianne Gensler⁶, ¹Vanderbilt University, Nashville, TN, ²Creighton University, Salt lake city, UT, ³University of Central Florida, Orlando, ⁴Winchester Medical Center, Winchester, VA, ⁵Mayo Clinic, Rochester, ⁶Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: While the use of biologics over the last decade has revolutionized treatment for some patients with axial SpA, only up to 40% reach remission…
Abstract Number: 0544 • ACR Convergence 2022
Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Atul Deodhar¹, Désirée van der Heijde², Lianne Gensler³, Huji Xu⁴, Karl Gaffney⁵, Hiroaki Dobashi⁶, Walter P Maksymowych⁷, Martin Rudwaleit⁸, Marina Magrey⁹, Dirk Elewaut¹⁰, Marga Oortgiesen¹¹, Carmen Fleurinck¹², Natasha de Peyrecave¹³, Alicia Ellis¹⁴, Thomas Vaux¹⁵, Julie Shepherd-Smith¹⁵ and Xenofon Baraliakos¹⁶, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China, ⁵Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ⁶Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁹Case Western Reserve University, University Hospitals, Richfield, OH, ¹⁰Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹³UCB Pharma, Brussels, Belgium, ¹⁴UCB Pharma, Raleigh, ¹⁵UCB Pharma, Slough, United Kingdom, ¹⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In patients (pts) with active ankylosing spondylitis (AS), BKZ…
Abstract Number: 1016 • ACR Convergence 2022
Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
Ivan Arias-de la Rosa¹, Elena Carnero-Montoro², lourdes Ladehesa-Pineda³, Clementina Lopez-Medina⁴, Rafaela Ortega-Castro¹, Maria del Carmen Abalos-Aguilera⁵, Daniel Dominguez-Toro⁶, Manuel Martinez-Bueno², Ruth Dominguez⁶, Olivia Castellini⁶, Guillermo Barturen², Chary López-Pedrera⁷, Eduardo Collantes¹, Marta Alarcon-Riquelme² and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁴Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁵Hospital Universitario Reina Sofia, Cordoba, Spain, ⁶GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors could be underestimating the subclinical atherosclerosis in patients with Spondyloarthritis (SpA). The identification of subclinical CVD sings and…
Abstract Number: 1160 • ACR Convergence 2022
Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
Jyotsna Soundararajan¹, Anu Shivalikanjli², Thomas Keane² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Overexpression of IL-23 using IL-23 minicircle DNA in B10.RIII mice results in the development of a spondyloarthritis-like disease. B10.RIII (B10.RIII-H2r H2-T18b/(71NS)SnJ) is a major…
Abstract Number: 1511 • ACR Convergence 2022
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
Dafna Gladman¹, Ghaydaa Aldabie², Fangya Ma³, Mitchell Sutton⁴, Ker-Ai Lee³ and Richard Cook³, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 0057 • ACR Convergence 2022
Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
Hannah Labinsky¹, Sophie von Rohr², Maria Gabriella Raimondo³, Ekaterina Vogt⁴, Britta Horstmann², Isabel Gehring⁵, Jessica Rojas-Restrepo⁵, Fabian Proft⁶, Felix Mühlensiepen⁷, Daniela Bohr², Georg Schett⁸, Andreas Ramming³ and Johannes Knitza³, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Thermo Fisher Scientific, Freiburg, Germany, ⁵Thermo Fisher Scientific, Freiburg, ⁶Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, ⁸Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: The growing shortage of rheumatologists threatens adequate rheumatological care. The diagnostic delay for axial spondyloarthritis (axSpA) is particularly long, ranging between 3 to 11…
Abstract Number: 0408 • ACR Convergence 2022
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Philip C. Robinson¹, Walter P Maksymowych², Lianne Gensler³, Martin Rudwaleit⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵, Mindy Kim⁶ and Atul Deodhar⁷, ¹University of Queensland School of Clinical Medicine, Brisbane, Australia, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Smyrna, GA, ⁷Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the…
Abstract Number: 0545 • ACR Convergence 2022
Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)
Cindy Weinstein¹, Paula Sliwinska-Stanczyk², Tomas Hala³, Marina Stanislav⁴, Anjela Tzontcheva⁵, Ruji Yao¹, Yuliya Berd¹, Sean Curtis¹ and George Philip¹, ¹Merck & Co., Inc., Rahway, NJ, ²Reumatika Centrum Reumatologii, Warsaw, Poland, ³Center for Clinical and Basic Research, Pardubice, Czech Republic, ⁴Vladimirsky Moscow Regional Scientific Institution, Moscow, Russia, ⁵MSD Switzerland, Zürich, Switzerland
Background/Purpose: Non-radiographic axial spondyloarthrits (nr-axSpA) is a rheumatic disease that is predominantly associated with chronic back pain and stiffness.1 Results from the Phase III GO-AHEAD…
Abstract Number: 1020 • ACR Convergence 2022
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
Vartika Kesarwani¹, Stephanie Sinnappan², M. Elaine Husni³, Michael Weisman⁴ and Joerg Ermann⁵, ¹University of Connecticut, Farmington, CT, ²Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or…
Abstract Number: 1165 • ACR Convergence 2022
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
Marie Beaufrère¹, Manon Jacoutot¹, Amel Ait Ali Said¹, Roula Said-Nahal², Gina Cosentino³, Chiara Rizzo³, Maxime Breban⁴ and Simon Glatigny⁴, ¹Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, ²Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ³INSERM 1173, Montigny-le-Bretonneux, France, ⁴1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France
Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
Abstract Number: 1512 • ACR Convergence 2022
What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain
Nelly Ziade¹, Avin Maroof², Bassel Elzorkany³, Nizar Ani⁴, ASAL ADNAN RIDHA⁵, Ahmed Abogamal⁶, Sahar Saad⁷, Lina El Kibbi⁸, Samar Al emadi⁹, Atheer Al Ansari¹⁰, Antonella Abi Najm¹, Tonine Younan¹, Khalil Kharrat¹, Joseph Maarrawi¹, Amer Sebaaly¹, Rami El Rachkidi¹, Torsten Witte¹¹ and Xenofon Baraliakos¹², ¹Saint-Joseph University, Beirut, Lebanon, ²Rizgary Teaching Hospital - Erbil, Erbil, Iraq, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Baghdad College of Medicine, Baghdad, Iraq, ⁵Baghdad Teaching Hospital, Baghdad, Iraq, ⁶Saudi German Hospital Dubai, Dubai, United Arab Emirates, ⁷King Hamad University Hospital, Al Sayh, Bahrain, ⁸Specialized Medical Center, Riyadh, Saudi Arabia, ⁹Hamad Medical Corporation, Doha, Qatar, ¹⁰Mediclinic, Abu Dhabi, United Arab Emirates, ¹¹MH-Hannover, Hannover, Germany, ¹²Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The diagnosis of axial spondyloarthritis (axSpA) is often delayed, due to the referral issues and, in certain regions of the world, the low prevalence…
Abstract Number: 2122 • ACR Convergence 2022
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna Gladman¹, Lars Erik², Diamant Thaci³, Paolo Gisondi⁴, Laure Gossec⁵, M. Elaine Husni⁶, Alice Gottlieb⁷, Hiroaki Dobashi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and William Tillett¹², ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ³Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ⁴Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁵Sorbonne Université, Paris, France, ⁶Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
Abstract Number: 0373 • ACR Convergence 2022
Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
Cristiana Sieiro Santos¹, Isabel Sendino Tenorio¹, Carolina Álvarez Castro¹, Clara Moriano Morales², Miguel Cordero Coma¹ and Elvira Díez Álvarez¹, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital León, León, Spain
Background/Purpose: Uveitis is the most frequent extra-articular manifestation of spondylarthritis (SpA), characterized by a sudden onset, often unilateral, anterior and recurrent and may be the…
Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Philip J Mease¹, Atul Deodhar², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Helena Marzo-Ortega⁶, Martin Rudwaleit⁷, Christine de la Loge⁸, Alicia Ellis⁹, Carmen Fleurinck¹⁰, Marga Oortgiesen¹¹, Vanessa Taieb¹² and Lianne Gensler¹³, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University, University Hospitals, Richfield, OH, ⁶Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, ¹⁰UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Colombes, France, ¹³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].